

# Yanjie Hao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1780157/publications.pdf>

Version: 2024-02-01

34  
papers

751  
citations

686830

13  
h-index

552369

26  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1067-1077.	2.9	139
2	Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. <i>European Respiratory Journal</i> , 2014, 44, 963-972.	3.1	110
3	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 7.	1.6	95
4	Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2021, 11, 633032.	1.3	53
5	Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1742-1752.	0.8	41
6	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	0.9	24
7	Mortality of Chinese patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2020, 39, 1569-1579.	1.0	23
8	High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT). <i>Medicine (United States)</i> , 2016, 95, e3968.	0.4	22
9	Systemic lupus erythematosus: year in review 2019. <i>Chinese Medical Journal</i> , 2020, 133, 2189-2196.	0.9	20
10	Addison's disease secondary to connective tissue diseases: a report of six cases. <i>Rheumatology International</i> , 2009, 29, 647-650.	1.5	18
11	A Rare Variant (rs933717) at <i>FBXO31</i> in Chinese Is Associated With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 287-297.	2.9	18
12	"Not at target": prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	1.6	17
13	Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 3400-3407.	0.9	15
14	Phenotype and function of macrophage polarization in monocrotaline-induced pulmonary arterial hypertension rat model. <i>Physiological Research</i> , 2021, 70, 213-226.	0.4	15
15	Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 997-1003.	0.5	15
16	Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 123.	1.6	14
17	The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature. <i>Clinical Rheumatology</i> , 2021, 40, 1131-1139.	1.0	13
18	Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. <i>Rheumatology</i> , 2022, 62, 181-189.	0.9	13

#	ARTICLE	IF	CITATIONS
19	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1255-1257.	0.9	12
20	Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells. <i>International Journal of Medical Sciences</i> , 2017, 14, 820-828.	1.1	10
21	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. <i>Clinical Rheumatology</i> , 2022, 41, 357-366.	1.0	10
22	Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 820-828.	0.4	10
23	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021, 60, 5185-5193.	0.9	9
24	Fibroblastic rheumatism: An addition to fibromatosis. <i>Joint Bone Spine</i> , 2011, 78, 519-521.	0.8	7
25	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 2033-2041.	1.5	6
26	Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2021, 23, 275.	1.6	5
27	Cysteine-rich protein 61 as a novel biomarker in systemic lupus erythematosus-associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 623-632.	0.4	5
28	Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 651-657.	0.9	4
29	Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study. <i>Lupus Science and Medicine</i> , 2022, 9, e000553.	1.1	4
30	Predicting lupus low disease activity state and remission in SLE: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1083-1089.	1.3	3
31	OP0250...INFLUENTIAL FACTORS IN PROMOTING TREAT-TO-TARGET FOR SYSTEMIC LUPUS ERYTHEMATOSUS VIA EMPOWERING PATIENTS: A COHORT STUDY FROM CHINA BY SMART SYSTEM OF DISEASE MANAGEMENT (SSDM). , 2019, , .		1
32	Performance of routine assessment of patient index data 3 (RAPID3) in monitoring disease activity of Chinese rheumatoid arthritis patients. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1940-1945.	0.9	0
33	AB0243...CYSTEINE RICH 61 (CYR61): A POTENTIAL BIOMARKER ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS. , 2019, , .		0
34	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. <i>Rheumatology and Immunology Research</i> , 2021, 2, 63-78.	0.2	0